Cherokee Insurance Co Acquires Shares of 7,213 Sanofi $SNY

Cherokee Insurance Co bought a new position in Sanofi (NASDAQ:SNY) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 7,213 shares of the company’s stock, valued at approximately $348,000.

A number of other large investors have also made changes to their positions in SNY. Accent Capital Management LLC purchased a new stake in shares of Sanofi in the 1st quarter valued at approximately $29,000. Eastern Bank raised its stake in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares during the period. Ameritas Advisory Services LLC purchased a new stake in shares of Sanofi in the second quarter valued at $28,000. Banque Transatlantique SA acquired a new stake in shares of Sanofi in the first quarter worth $33,000. Finally, Brentview Investment Management LLC acquired a new position in Sanofi during the first quarter valued at $42,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Trading Up 0.4%

NASDAQ:SNY opened at $51.92 on Thursday. The company’s 50 day moving average is $48.75 and its 200-day moving average is $49.45. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12. The firm has a market cap of $127.49 billion, a price-to-earnings ratio of 12.16, a P/E/G ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. The business had revenue of $14.53 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. Sanofi’s revenue was down 7.5% compared to the same quarter last year. During the same period last year, the business posted $2.25 EPS. Equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.